CR-4056 is under clinical development by Rottapharm Biotech and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CR-4056’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CR-4056 overview
CR-4056 is under development for the treatment of moderate to severe chronic pain in patients with osteoarthritis and post-operative pain. The drug candidate is administered orally in the form of a capsule. It is a small molecule synthetic compound (new chemical entity). The drug candidate is an imidazoline (I2) ligand with analgesic activities. It was under development for the treatment of fibromyalgia, neuropathic pain, and acute nonspecific pain.
Rottapharm Biotech overview
Rottapharm Biotech (Rottapharm), a subsidiary of Fidim Srl is a research company focused on the discovery and development of innovative drugs. The company’s pipeline products include CR4056, 12 ligand for analgesia; CR6086 which is a EP4 receptor antagonist for immunomodulation in RA; CR6086 a EP4 receptor antagonist for immuno-oncology; CR13626 for glioblastoma; CR10049 an Inflammatory OA disease modification; CR14629 which is a metabolic OA disease modification. Rottapharm develops therapies based on its proprietary technology platform for the generation and selection of monoclonal antibodies. Rottapharm is headquartered in Monza, Italy.
For a complete picture of CR-4056’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
